EP2480579A4 - Methods of treating inflammation - Google Patents

Methods of treating inflammation

Info

Publication number
EP2480579A4
EP2480579A4 EP10819481.2A EP10819481A EP2480579A4 EP 2480579 A4 EP2480579 A4 EP 2480579A4 EP 10819481 A EP10819481 A EP 10819481A EP 2480579 A4 EP2480579 A4 EP 2480579A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating inflammation
inflammation
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10819481.2A
Other languages
German (de)
French (fr)
Other versions
EP2480579A2 (en
Inventor
Jurgen Bernhagen
Christian Weber
Benedikt Vollrath
Court Turner
Joshua Robert Schultz
Alma Zernecke
Sergio Duron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carolus Therapeutics Inc
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of EP2480579A2 publication Critical patent/EP2480579A2/en
Publication of EP2480579A4 publication Critical patent/EP2480579A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10819481.2A 2009-09-23 2010-09-23 Methods of treating inflammation Withdrawn EP2480579A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US31903910P 2010-03-30 2010-03-30
PCT/US2010/050047 WO2011038149A2 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Publications (2)

Publication Number Publication Date
EP2480579A2 EP2480579A2 (en) 2012-08-01
EP2480579A4 true EP2480579A4 (en) 2013-07-31

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10819481.2A Withdrawn EP2480579A4 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Country Status (9)

Country Link
EP (1) EP2480579A4 (en)
KR (1) KR20120105429A (en)
CN (1) CN102725311A (en)
AU (1) AU2010298249A1 (en)
BR (1) BR112012006468A2 (en)
CA (1) CA2773978A1 (en)
IN (1) IN2012DN02423A (en)
MX (1) MX2012003514A (en)
WO (1) WO2011038149A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NZ702315A (en) * 2012-05-17 2016-10-28 Cyon Therapeutics Inc Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors
AR098418A1 (en) * 2013-11-14 2016-05-26 Baxter Healthcare Sa INHIBITORY FACTOR OF IMMIGRATION OF MACROPHAGUS (MIF) AS THERAPEUTIC OBJECTIVE
BR112018068393A2 (en) 2016-03-11 2019-01-15 Ardea Biosciences Inc cxcr-2 inhibitors for the treatment of crystal arthropathy disorders
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
EP3884277A1 (en) * 2018-12-26 2021-09-29 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
MX2022011231A (en) * 2020-03-11 2022-11-07 Biolinerx Ltd CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DIFFICULTY SYNDROME AND VIRAL INFECTIONS.
WO2021219495A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN112656934A (en) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 Application of polypeptide AT03 in medicine for treating primary biliary cholangitis
EP4378319A1 (en) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprising bioactive peptides
CN119318647A (en) * 2024-08-14 2025-01-17 南方医科大学 Application of SB225002 in preparation of medicine for treating myocardial infarction and composition for treating myocardial infarction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20040009149A1 (en) * 2002-02-27 2004-01-15 Altman John D. Multimeric binding complexes
JP4472351B2 (en) * 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド Internalizing anti-CD74 antibody and method of use thereof
WO2005065328A2 (en) * 2003-12-30 2005-07-21 The United States Of America, As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2009117706A2 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FILIP ANA-MARIA ET AL: "Ribosomal protein S19 interacts with macrophage migration inhibitory factor and attenuates its pro-inflammatory function", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 284, no. 12, 20 March 2009 (2009-03-20), pages 7977 - 7985, XP002575465, ISSN: 0021-9258, [retrieved on 20090120], DOI: 10.1074/JBC.M808620200 *
JÜRGEN BERNHAGEN ET AL: "MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 13, no. 5, 5 March 2007 (2007-03-05), pages 587 - 596, XP008140753, ISSN: 1078-8956, DOI: 10.1038/NM1567 *
VERA PEDRO L ET AL: "Cyclophosphamide-Induced Cystitis Increases Bladder CXCR4 Expression and CXCR4-Macrophage Migration Inhibitory Factor Association", PLOS ONE, vol. 3, no. 12, December 2008 (2008-12-01), XP002699221, ISSN: 1932-6203 *
WEBER CHRISTIAN ET AL: "Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 105, no. 42, October 2008 (2008-10-01), pages 16278 - 16283, XP002699220, ISSN: 0027-8424 *
WEBER ET AL: "Abstract: 559 CHEMOKINES AS THERAPEUTIC TARGETS IN ATHEROSCLEROSIS", ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER, AMSTERDAM, NL, vol. 10, no. 2, 1 June 2009 (2009-06-01), pages e1684 - e1685, XP026781902, ISSN: 1567-5688, [retrieved on 20090601], DOI: 10.1016/S1567-5688(09)71632-0 *

Also Published As

Publication number Publication date
AU2010298249A1 (en) 2012-04-19
MX2012003514A (en) 2012-04-19
CA2773978A1 (en) 2011-03-31
IN2012DN02423A (en) 2015-08-21
KR20120105429A (en) 2012-09-25
BR112012006468A2 (en) 2016-08-09
WO2011038149A2 (en) 2011-03-31
CN102725311A (en) 2012-10-10
WO2011038149A3 (en) 2011-10-27
EP2480579A2 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
IL207752A0 (en) Methods of treating inflammation
EP2331564A4 (en) Methods of treating inflammation
ZA201304280B (en) Treatment of jak2-mediated conditions
IL226401A0 (en) Methods of treating fgf21-associated disorders
EP2480579A4 (en) Methods of treating inflammation
IL208354A0 (en) Methods of treatment
IL207439A0 (en) Methods of treating inflammatory pain
PL2435825T3 (en) Methods of treating diseases
GB0915515D0 (en) Treatment of vasculoproliferative conditions
IL214664A0 (en) Methods of treating hair related conditions
IL215592A0 (en) Compositions and methods for the treatment of inflammation
GB201018147D0 (en) Method of treatment
EP2643001A4 (en) Method of treating cancer
IL233111A0 (en) Treatment of inflammation
IL206491A0 (en) Treatment of produce
IL256026B (en) Methods of treatment
DK2473482T3 (en) Methods of treating orthomyxoviral infections
GB201003920D0 (en) Method of treatment
GB0901456D0 (en) Treatment of psoriasis
IL218230A0 (en) Method of treating cancer
IL200753A0 (en) Treatment of psoriasis
ZA201108493B (en) Method of treating hair
GB201012926D0 (en) Compounds for treatment of inflammation
GB0908101D0 (en) Treatment of stress
GB201018149D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120314

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DURON, SERGIO

Inventor name: WEBER, CHRISTIAN

Inventor name: SCHULTZ, JOSHUA, ROBERT

Inventor name: TURNER, COURT

Inventor name: VOLLRATH, BENEDIKT

Inventor name: BERNHAGEN, JURGEN

Inventor name: ZERNECKE, ALMA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130702

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 19/00 20060101AFI20130624BHEP

Ipc: A61P 35/00 20060101ALI20130624BHEP

Ipc: C07K 14/435 20060101ALI20130624BHEP

Ipc: C07K 7/06 20060101ALI20130624BHEP

Ipc: C07K 7/08 20060101ALI20130624BHEP

Ipc: A61K 38/18 20060101ALI20130624BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140130